8-K: Oramed Pharmaceuticals Extends Maturity Date on Scilex Promissory Note, Receives Shares as Consideration

Oramed Pharmaceuticals has amended its senior secured promissory note with Scilex Holding Company, extending the maturity date and receiving shares of Scilex common stock in return.

Summary

• Oramed Pharmaceuticals Inc. has agreed to amend a Senior Secured Promissory Note with Scilex Holding Company.
• The amendment extends the maturity date of the note from March 21, 2025, to December 31, 2025.
• In exchange for the extension, SCLX Stock Acquisition JV LLC will transfer 3,250,000 shares of Scilex common stock to Oramed.
• The amendment also modifies the definition of Cash Sweep Financing and allows Oramed to direct prepayments to other note holders.
• A new covenant prevents Scilex from increasing compensation or granting additional equity to its officers, directors, or senior management while the note is outstanding.
• The original principal amount of the note was $101,875,000, with $7,675,000 remaining outstanding.

Sentiment

Score: 4

Explanation: The document indicates a negative development with the need for a debt extension, although the receipt of Scilex shares provides some offset. The overall sentiment is cautious due to the potential financial strain at Scilex.

Positives

• Oramed receives 3,250,000 shares of Scilex common stock, adding to its assets.
• The extension of the maturity date provides Oramed with more time to receive repayment of the outstanding $7,675,000.
• The new covenant restricting Scilex's management compensation provides additional protection for Oramed's investment.
• The flexibility to direct prepayments to other note holders could potentially improve Oramed's overall financial position.

Negatives

• The extension of the maturity date means Oramed will not receive the remaining $7,675,000 until December 31, 2025, delaying cash flow.
• The need for an extension suggests potential financial difficulties at Scilex, which could impact Oramed's investment.

Risks

• Scilex's ability to repay the $7,675,000 by the extended maturity date is not guaranteed.
• The value of the 3,250,000 Scilex shares received by Oramed could fluctuate, impacting the overall value of the transaction.
• The amendment indicates potential financial strain at Scilex, which could lead to further issues for Oramed.

Future Outlook

The amendment extends the repayment timeline for the outstanding debt, and the value of the Scilex shares will be a factor in Oramed's future financial position. The ability to direct prepayments to other note holders provides some flexibility.

Management Comments

• Nadav Kidron, President and CEO of Oramed Pharmaceuticals, signed the report on behalf of the company.

Industry Context

This amendment reflects the ongoing financial challenges faced by some companies in the biotech and pharmaceutical sectors, where debt restructuring and extensions are not uncommon. It also highlights the complex interdependencies between companies through debt and equity holdings.

Comparison to Industry Standards

• Debt restructuring and maturity extensions are common in the biotech industry, especially for companies with high cash burn rates.
• The use of equity as consideration for debt extensions is also a common practice, particularly when cash is constrained.
• The specific terms of this agreement, such as the share transfer and prepayment options, are tailored to the unique circumstances of Oramed and Scilex.

Stakeholder Impact

• Shareholders of Oramed may be concerned about the delayed repayment and the potential risks associated with Scilex's financial health.
• Creditors of Scilex may be impacted by the changes to the debt structure.
• Employees of Scilex may be affected by the restrictions on compensation and equity awards.

Next Steps

• Oramed will monitor Scilex's financial performance and ability to repay the debt by the extended maturity date.
• Oramed will evaluate the value of the Scilex shares received as consideration.
• Oramed will assess the impact of the prepayment options on its overall financial strategy.

Key Dates

Keywords

Promissory Note, Maturity Date Extension, Scilex Holding Company, Oramed Pharmaceuticals, Share Transfer, Debt Financing, Cash Sweep Financing, Senior Secured Note